Equibles does not estimate personal net worth.
Get an email with a short summary when Aurinia Pharmaceuticals Inc. publishes a filing, an earnings call transcript or a press release.
Get AUPH alertsJoseph Miller is recorded as CFO at Aurinia Pharmaceuticals Inc. (AUPH). The newest filing on record that lists Joseph Miller as CFO at Aurinia Pharmaceuticals Inc. (AUPH) is dated April 21, 2026. Joseph Miller was last confirmed as Board Member at Avalo Therapeutics, Inc. (AVTX) in a filing dated April 27, 2021. The proxy statement of Aurinia Pharmaceuticals Inc. reports total compensation of $2,102,747 for Joseph Miller in fiscal 2025, including a base salary of $526,988. Disclosed compensation is on record for 6 fiscal years. Joseph Miller has spoken on 6 earnings calls across 1 company, most recently for Aurinia Pharmaceuticals Inc. on November 4, 2025. Aurinia Pharmaceuticals Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Aurinia Pharmaceuticals Inc. includes Jeffrey Bailey (CEO and Board Member), Kevin Tang (CEO and Board Member), Peter Greenleaf (CEO and Board Member) and 7 others.
“For the third quarter of 2025, total revenue was $73.5 million, up 8% from $67.8 million in the same period of 2024. As a reminder, the 2024 period included a milestone payment of $10 million associated with LUPKYNIS regulatory approval in Japan.”
“Joining me on the call this morning are Peter Greenleaf, Aurinia's President and Chief Executive Officer, and Dr. Greg Keenan, Aurinia's Chief Medical Officer.”
“Let's take a few minutes and go into detail regarding our financial results for the first quarter of 2024. Total net revenue was $50.3 million and $34.4 million for the 3 months ended March 31, 2024, and March 31, 2023, respectively.”
“At December 31, 2022, we had cash, cash equivalents, restricted cash and investments of $389.4 million compared to $466.1 million in the prior year.”
“On the financial front, Aurinia ended the third quarter of 2020 with cash, cash equivalents and investments of $421 million compared to $306 million at December 31, 2019.”
Start not stated–present
Last confirmed April 21, 2026
2020-01-01–2021-04-27
Last confirmed by a filing; no departure on record
Biotechnology · Healthcare
CFO
Biotechnology · Healthcare
Board Member
Since 2020-01-01, last confirmed 2021-04-27
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Aurinia Pharmaceuticals Inc. (AUPH) | Former Chief Financial Officer | $526,988 | $2,102,747 |
| 2024 | Aurinia Pharmaceuticals Inc. (AUPH) | Former Chief Financial Officer | $500,701 | $2,297,805 |
| 2023 | Aurinia Pharmaceuticals Inc. (AUPH) | Former Chief Financial Officer | $500,701 | $3,976,937 |
| 2020 | Avalo Therapeutics, Inc. (AVTX) | Former Chief Financial Officer, former principal financial officer, and former principal executive officer | $116,748 | $232,269 |
| 2019 | Avalo Therapeutics, Inc. (AVTX) | Former Chief Financial Officer, former principal financial officer, and former principal executive officer | $356,000 | $1,170,598 |
| 2018 | Avalo Therapeutics, Inc. (AVTX) | Former Chief Financial Officer, former Principal Financial Officer, and former Principal Executive Officer | $153,600 | $672,985 |
